secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2026-02-20T23:59:59+00:00
Accession:  0001104659-26-017870
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Audit Committee completes biosimilar purchase review, finds no improper conduct
--------------------------------------------------------------------------------

- Audit Committee completed independent review of timing of biosimilar purchases from a supplier in prior years.
- Review found no evidence of improper conduct and no adjustments to previously issued financial statements.
- Company intends to file its Form 10-K for the year ended December 31, 2025 on time.
- No changes required to SEC disclosures related to the transactions reviewed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465926017870/0001104659-26-017870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465926017870/tm266880d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-017870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer